Donanemab Receives CHMP Positive Opinion as Treatment for Early Symptomatic Alzheimer Disease

Donanemab has received a positive opinion from the European Medicines Agency’s CHMP for the treatment of early symptomatic Alzheimer disease, bringing Eli Lilly’s anti-amyloid therapy one step closer to approval in the European Union.